上海医药
上海醫藥
상해의약
Shanghai Medical & Pharmaceutical Journal
2015年
17期
41-42,54
,共3页
缺氧诱导因子-1a%非小细胞肺癌%化疗%敏感性
缺氧誘導因子-1a%非小細胞肺癌%化療%敏感性
결양유도인자-1a%비소세포폐암%화료%민감성
hypoxia inducible factor-1a%non small cell lung cancer%chemotherapy%sensitivity
目的：探讨 HIF-1a 表达对晚期非小细胞肺癌（NSCLC）患者的化疗敏感性。方法：选取我院收治的晚期NSCLC 化疗患者92例，采用免疫组织化学法检测 HIF-1a 的表达，分析 HIF-1a 表达与化疗疗效的关系。结果：HIF-1a 主要表达于肺癌细胞胞核及胞质，呈明显的异质性；HIF-1a 不同表达患者间化疗有效率和疾病控制率比较差异无统计学意义（P ＞0.05）。结论：HIF-1a 的表达状态与化疗近期疗效无明显相关性，尚不能确定为晚期 NSCLC 患者化疗疗效的预测因子。
目的：探討 HIF-1a 錶達對晚期非小細胞肺癌（NSCLC）患者的化療敏感性。方法：選取我院收治的晚期NSCLC 化療患者92例，採用免疫組織化學法檢測 HIF-1a 的錶達，分析 HIF-1a 錶達與化療療效的關繫。結果：HIF-1a 主要錶達于肺癌細胞胞覈及胞質，呈明顯的異質性；HIF-1a 不同錶達患者間化療有效率和疾病控製率比較差異無統計學意義（P ＞0.05）。結論：HIF-1a 的錶達狀態與化療近期療效無明顯相關性，尚不能確定為晚期 NSCLC 患者化療療效的預測因子。
목적：탐토 HIF-1a 표체대만기비소세포폐암（NSCLC）환자적화료민감성。방법：선취아원수치적만기NSCLC 화료환자92례，채용면역조직화학법검측 HIF-1a 적표체，분석 HIF-1a 표체여화료료효적관계。결과：HIF-1a 주요표체우폐암세포포핵급포질，정명현적이질성；HIF-1a 불동표체환자간화료유효솔화질병공제솔비교차이무통계학의의（P ＞0.05）。결론：HIF-1a 적표체상태여화료근기료효무명현상관성，상불능학정위만기 NSCLC 환자화료료효적예측인자。
Objective: To investigate the effect of the expression of HIF-1a on the chemotherapeutic sensitivity of patients with advanced non-small cell lung cancer (NSCLC). Methods: Ninety-two cases of patients with advanced NSCLC chemotherapy in our hospital were selected. The expression of HIF-1a was detected by immunohistochemistry and the relationship between the expression of HIF-1a and the efficacy of chemotherapy was analyzed. Results: HIF-1a was mainly expressed in the cytoplasm and nucleus of lung cancer cells, and its expression showed significant heterogeneity. There was no significant difference in the effective rate and the disease control rate between patients with different expression (P>0.05). Conclusion: The status of HIF-1a expression was not correlated with the short-term efficacy of chemotherapy, and is not a predictor for the efficacy of chemotherapy in patients with advanced NSCLC.
